Investment case
Imara Inc.
IRON · 2 developments mapped · last assessed 2026-09-01
Market Ontology has mapped 2 macro, policy, and market developments to Imara Inc. since 2026-09-01. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for IRON yet, so no modelled value is shown. The IRON valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run IRON on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026
Indirect competitive landscape shift in hematologic disorders, particularly myelofibrosis, if DISC-0974 data is compelling.
· Moves competitive intensity in myelofibrosis market, market share potential for competing therapies
What changed, by assumption
- 2026-09-01Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026
- 2026-09-01Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-06-30 | Cost of capital | Bullish | Higher cost-of-debt tranche lifts blended WACC. | 0.70 |
| 2026-06-30 | Interest expense | Bullish | High-yield coupon materially raises interest burden. | 0.70 |
| 2026-06-30 | Net debt | Bullish | Sub-IG debt raise increases leverage and net debt. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-01 | Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026 | watch | 1-3m | 0.40 |
| 2026-09-01 | Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO | watch | 1-3m | 0.30 |